Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
Objectives: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myoca...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
BMJ Publishing Group
2012
|
| _version_ | 1826282965983821824 |
|---|---|
| author | Preiss, D Thomas, L Sun, J Haffner, S Holman, R Standl, E Leiter, L Mazzone, T Rutten, G Tognoni, G Martinez, F Chiang, F Califf, R McMurray, J |
| author_facet | Preiss, D Thomas, L Sun, J Haffner, S Holman, R Standl, E Leiter, L Mazzone, T Rutten, G Tognoni, G Martinez, F Chiang, F Califf, R McMurray, J |
| author_sort | Preiss, D |
| collection | OXFORD |
| description | Objectives: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and (2) cardiovascular death, among patients with IGT. Design: We studied participants enrolled in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Predictors of cardiovascular events were identified in observational analyses. Setting: Clinical trial participants in 40 countries. Participants: 9306 participants with biochemically confirmed IGT at high risk of cardiovascular events participated in NAVIGATOR. Primary and secondary outcome measures: Cox proportional hazard regression models were constructed using variables (demographic data, medical history, clinical features, biochemical results and ECG findings) recorded at baseline to identify variables associated with and predictive of cardiovascular events. Results: Over 6.4 years, 639 (6.9%) participants experienced a cardiovascular event, and 244 (2.6%) cardiovascular death. While predictors of both outcomes included established risk factors such as existing cardiovascular disease, male gender, older age, current smoking status and higher low-density lipoprotein cholesterol, other variables such as reduced estimated glomerular filtration rate, previous thromboembolic disease, atrial fibrillation, higher urinary albumin/creatinine ratio and chronic obstructive pulmonary disease were also important predictors. Glycaemic measures were not predictive of cardiovascular events. c-Statistics for predicting cardiovascular events and cardiovascular death were 0.74 and 0.82, respectively. This compares with c-statistics for cardiovascular events and cardiovascular death of 0.65 and 0.71, respectively, using the classical Framingham risk factors of age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension and smoking status. |
| first_indexed | 2024-03-07T00:51:49Z |
| format | Journal article |
| id | oxford-uuid:86a9004f-575a-45cc-8607-04b4c09b1383 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:51:49Z |
| publishDate | 2012 |
| publisher | BMJ Publishing Group |
| record_format | dspace |
| spelling | oxford-uuid:86a9004f-575a-45cc-8607-04b4c09b13832022-03-26T22:05:33ZPredictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:86a9004f-575a-45cc-8607-04b4c09b1383EnglishSymplectic Elements at OxfordBMJ Publishing Group2012Preiss, DThomas, LSun, JHaffner, SHolman, RStandl, ELeiter, LMazzone, TRutten, GTognoni, GMartinez, FChiang, FCaliff, RMcMurray, JObjectives: Risk factors for cardiovascular events are well established in general populations and those with diabetes but have been sparsely studied in impaired glucose tolerance (IGT). We sought to identify predictors of (1) a composite cardiovascular outcome (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and (2) cardiovascular death, among patients with IGT. Design: We studied participants enrolled in the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. Predictors of cardiovascular events were identified in observational analyses. Setting: Clinical trial participants in 40 countries. Participants: 9306 participants with biochemically confirmed IGT at high risk of cardiovascular events participated in NAVIGATOR. Primary and secondary outcome measures: Cox proportional hazard regression models were constructed using variables (demographic data, medical history, clinical features, biochemical results and ECG findings) recorded at baseline to identify variables associated with and predictive of cardiovascular events. Results: Over 6.4 years, 639 (6.9%) participants experienced a cardiovascular event, and 244 (2.6%) cardiovascular death. While predictors of both outcomes included established risk factors such as existing cardiovascular disease, male gender, older age, current smoking status and higher low-density lipoprotein cholesterol, other variables such as reduced estimated glomerular filtration rate, previous thromboembolic disease, atrial fibrillation, higher urinary albumin/creatinine ratio and chronic obstructive pulmonary disease were also important predictors. Glycaemic measures were not predictive of cardiovascular events. c-Statistics for predicting cardiovascular events and cardiovascular death were 0.74 and 0.82, respectively. This compares with c-statistics for cardiovascular events and cardiovascular death of 0.65 and 0.71, respectively, using the classical Framingham risk factors of age, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension and smoking status. |
| spellingShingle | Preiss, D Thomas, L Sun, J Haffner, S Holman, R Standl, E Leiter, L Mazzone, T Rutten, G Tognoni, G Martinez, F Chiang, F Califf, R McMurray, J Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
| title | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
| title_full | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
| title_fullStr | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
| title_full_unstemmed | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
| title_short | Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial |
| title_sort | predictors of cardiovascular events in a contemporary population with impaired glucose tolerance an observational analysis of the nateglinide and valsartan in impaired glucose tolerance outcomes research navigator trial |
| work_keys_str_mv | AT preissd predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT thomasl predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT sunj predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT haffners predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT holmanr predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT standle predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT leiterl predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT mazzonet predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT rutteng predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT tognonig predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT martinezf predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT chiangf predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT califfr predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial AT mcmurrayj predictorsofcardiovasculareventsinacontemporarypopulationwithimpairedglucosetoleranceanobservationalanalysisofthenateglinideandvalsartaninimpairedglucosetoleranceoutcomesresearchnavigatortrial |